Hepatitis C overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
'''Hepatitis C''' is a [[Blood-borne disease|blood-borne]], infectious, [[virus|viral]] disease that is caused by a hepatotropic virus called ''[[Hepatitis C virus]]'' ('''HCV'''). The infection can cause [[liver]] inflammation ([[hepatitis]]) that is often asymptomatic, but ensuing chronic hepatitis can result later in [[cirrhosis]] ([[Fibrosis|fibrotic scarring]] of the liver) and [[hepatocellular carcinoma|liver cancer]].
Hepatitis C virus (HCV) is a single-stranded RNA virus that causes liver injury. Initially discovered in 1989, HCV was found to be a bloodborne infection that persists into chronic state in the majority of cases. Although the exact pathogenesis and life cycle of HCV is poorly understood, it has been demonstrated that impaired innate and adaptive immunity to acute HCV may contribute to the development of chronic infection. While the transfusion of blood and blood products, along with injectable therapy, were considered the most common risk factors for HCV in the past, the use of injectable illicit drugs are currently the most important risk factor. In the absence of treatment, chronic HCV continues to lead liver cirrhosis several years after the initial infection, a course complicated by decompensated liver failure or hepatocellular carcinoma. Other extrahepatic manifestations are also common. Specific patient populations should be screened for HCV first using HCV serological testing, or rarely directly by HCV RNA in patients who have had previous HCV exposure, treatment-induced clearance, or immunosuppression. The diagnosis is made when anti-HCV and HCV RNA both demonstrate positive results.
 
The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's [[blood]]. The symptoms can be medically managed, and a proportion of patients can be cleared of the virus by a long course of anti-viral medicines.  Although early medical intervention is helpful, people with HCV infection often experience mild symptoms, and consequently do not seek treatment. An estimated 150-200 million people worldwide are infected with hepatitis C. In the U.S., those with a history of intravenous drug use, inhaled drug usage, [[tattoo]]s, or who have been exposed to blood via unsafe sex or social practices are increased risk for this disease. Hepatitis C is the leading cause of [[liver transplant]] in the United States.


==References==
==References==

Revision as of 06:52, 28 July 2014

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C overview

CDC on Hepatitis C overview

Hepatitis C overview in the news

Blogs on Hepatitis C overview

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Yazan Daaboul; Serge Korjian

Overview

Hepatitis C virus (HCV) is a single-stranded RNA virus that causes liver injury. Initially discovered in 1989, HCV was found to be a bloodborne infection that persists into chronic state in the majority of cases. Although the exact pathogenesis and life cycle of HCV is poorly understood, it has been demonstrated that impaired innate and adaptive immunity to acute HCV may contribute to the development of chronic infection. While the transfusion of blood and blood products, along with injectable therapy, were considered the most common risk factors for HCV in the past, the use of injectable illicit drugs are currently the most important risk factor. In the absence of treatment, chronic HCV continues to lead liver cirrhosis several years after the initial infection, a course complicated by decompensated liver failure or hepatocellular carcinoma. Other extrahepatic manifestations are also common. Specific patient populations should be screened for HCV first using HCV serological testing, or rarely directly by HCV RNA in patients who have had previous HCV exposure, treatment-induced clearance, or immunosuppression. The diagnosis is made when anti-HCV and HCV RNA both demonstrate positive results.

References

Template:WH Template:WS

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Navigation menu